Literature DB >> 10375113

Tumor size predicts the survival of patients with pathologic stage T2 bladder carcinoma: a critical evaluation of the depth of muscle invasion.

L Cheng1, R M Neumann, B G Scherer, A L Weaver, B C Leibovich, A Nehra, H Zincke, D G Bostwick.   

Abstract

BACKGROUND: Accurate examination of radical cystectomy specimens is critical for stratifying patients into prognostically important groups and determining the need for adjuvant treatment. Evidence has accumulated that cancers invading the superficial muscle wall (T2a) behave similarly to those invading the deep muscle wall (T2b). Quantitative analysis of the depth of invasion in relation to patient outcome is needed.
METHODS: The authors systematically evaluated the depth of invasion by micrometer measurement and its relation to the survival of 64 patients with bladder carcinoma pathologic classification as pT2 who had long term follow-up after radical cystectomy. Numerous clinical and pathologic variables were analyzed with univariate and multivariate Cox proportional hazards models. The mean age of patients was 64 years, and their mean follow-up was 8.3 years.
RESULTS: There was no significant difference in clinical outcome between patients with T2a carcinoma and those with T2b. Lymph node metastasis and tumor size were each significantly associated with distant metastasis free and cancer specific survival. Ten-year distant metastasis free and cancer specific survival were 100% and 94%, respectively, for patients with tumors <3 cm (P = 0.006) and 68% and 73%, respectively, for patients with tumors > or = 3 cm (P = 0.005). After adjustment for lymph node status, tumor size maintained significance in predicting distant metastasis free survival (risk ratio, 1.5; 95% confidence interval, 1.1-2.0; P = 0.009) and cancer specific survival (risk ratio, 1.5; 95% confidence interval, 1.1-1.9; P = 0.01). Age was associated with recurrence free survival and all-cause survival. None of the other variables, including gender, vascular invasion, presence of carcinoma in situ, pathologic classification (T2a vs. T2b), depth of invasion, depth of muscle invasion, ratio of depth of invasion to bladder wall thickness, and percentage of muscle wall invasion, were significantly associated with patient outcome.
CONCLUSIONS: The findings of this study indicate that the subclassification of T2 bladder carcinoma by depth of muscle invasion is of no prognostic value; conversely, tumor size, an easily measured factor, is predictive of distant metastasis free and cancer specific survival.

Entities:  

Mesh:

Year:  1999        PMID: 10375113     DOI: 10.1002/(sici)1097-0142(19990615)85:12<2638::aid-cncr21>3.0.co;2-v

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  12 in total

1.  [Patients with bladder cancer in clinical stage T2 : survival benefit of downstaging in comparison to patients with confirmed muscle invasion in cystectomy specimens].

Authors:  M May; H-M Fritsche; S Brookman-May; M Burger; C Bolenz; L Trojan; E Herrmann; M S Michel; C Wülfing; A Tiemann; S C Müller; J Ellinger; A Buchner; C G Stief; D Tilki; W F Wieland; C Gilfrich; T Höfner; M Hohenfellner; A Haferkamp; J Roigas; M Zacharias; S Gunia; P J Bastian
Journal:  Urologe A       Date:  2010-12       Impact factor: 0.639

2.  Lymphovascular invasion in radical cystectomy specimen: is it an independent prognostic factor in patients without lymph node metastases?

Authors:  Murugesan Manoharan; Devendar Katkoori; T A Kishore; Merce Jorda; Tony Luongo; Mark S Soloway
Journal:  World J Urol       Date:  2009-07-12       Impact factor: 4.226

3.  Sub-100nm gold nanomatryoshkas improve photo-thermal therapy efficacy in large and highly aggressive triple negative breast tumors.

Authors:  Ciceron Ayala-Orozco; Cordula Urban; Sandra Bishnoi; Alexander Urban; Heather Charron; Tamika Mitchell; Martin Shea; Sarmistha Nanda; Rachel Schiff; Naomi Halas; Amit Joshi
Journal:  J Control Release       Date:  2014-07-19       Impact factor: 9.776

4.  Successful Treatment of a Large Superficial Bladder Cancer with Neoadjuvant Arterial Infusion Chemotherapy: A Case Report.

Authors:  Hiroshi Kano; Sotaro Miwa; Kiyoshi Koshida; Keiichi Kawai
Journal:  Case Rep Oncol       Date:  2018-06-18

5.  Clinical Significance of Squamous Differentiation in Urothelial Carcinoma of the Bladder.

Authors:  Akinori Minato; Hirotsugu Noguchi; Ikko Tomisaki; Atsushi Fukuda; Tatsuhiko Kubo; Toshiyuki Nakayama; Naohiro Fujimoto
Journal:  Cancer Control       Date:  2018 Jan-Dec       Impact factor: 3.302

6.  A co-expression network for differentially expressed genes in bladder cancer and a risk score model for predicting survival.

Authors:  Zihao Chen; Guojun Liu; Aslam Hossain; Irina G Danilova; Mikhail A Bolkov; Guoqing Liu; Irina A Tuzankina; Wanlong Tan
Journal:  Hereditas       Date:  2019-07-09       Impact factor: 3.271

7.  Five-Year Survival Rate of Bladder Cancer in Iran during 2001-2007.

Authors:  Maryam Khayamzadeh; Fereshte Aliakbari; Zahra Zolghadr; Majid Emadeddin; Mahsa Ahadi; MohammadEsmaeil Akbari; Amir Reza Abedi; Shahrzad Nematollahi; Jalil Hosseini
Journal:  Iran J Pathol       Date:  2020-10-10

8.  Pathways to clinical CLARITY: volumetric analysis of irregular, soft, and heterogeneous tissues in development and disease.

Authors:  Brian Hsueh; Vanessa M Burns; Philip Pauerstein; Katherine Holzem; Li Ye; Kristin Engberg; Ai-Chi Wang; Xueying Gu; Harini Chakravarthy; H Efsun Arda; Gregory Charville; Hannes Vogel; Igor R Efimov; Seung Kim; Karl Deisseroth
Journal:  Sci Rep       Date:  2017-07-19       Impact factor: 4.379

9.  Is it oncologically and clinically safe to adopt a bladder sparing approach in complete responders following neoadjuvant chemotherapy alone without proceeding to a radical cystectomy?

Authors:  Ranjan Arianayagam; Anand Sharma; Nikhil Vasdev
Journal:  Transl Androl Urol       Date:  2018-12

10.  Trimodal therapy in T2-4aN0M0 bladder cancer--How to select the best candidate?

Authors:  Ofer N Gofrit; Amichay Meirovitz; Stephen Frank; Igal Rabinovich; Hemda Luwisch; Vladimir Yutkin; Tzahi Neuman; Guy Hidas; Mordechai Duvdevani; Marc Wygoda
Journal:  Cancer Med       Date:  2020-09-22       Impact factor: 4.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.